Impacto prognóstico da expressão de micrornas no câncer de mama
revisão sistemática
Palavras-chave:
microRNA, câncer de mama, prognósticoResumo
O câncer de mama é um importante problema de saúde em todo o mundo e a identificação de novos marcadores prognósticos é necessária para estabelecer o melhor tratamento para cada paciente. MicroRNAs (miRNAs) são RNAs não codificadores reguladores da expressão gênica que têm sido evidenciados como biomarcadores úteis no prognóstico do câncer de mama. O objetivo desta revisão sistemática foi verificar o papel da expressão de miRNAs tumorais associados aos fatores prognósticos dos carcinomas de mama. A busca de estudos foi feita no banco de dados PubMed; 1.457 artigos foram inicialmente encontrados e 20 estudos foram incluídos na revisão. MiRNA-21 e miRNA-200b foram os mais comumente investigados em relação ao prognóstico do câncer de mama. A presença de metástase linfonodal foi significativamente associada à hiperexpressão de miRNA-211, miRNA-301a e miRNA-370 e também associada à hipoexpressão de miRNA-124, miRNA-127, miRNA-129-5p, miRNA199-5p, miRNA-206, miRNA-218 e miRNA- 339-5p. Metástase a distância foi associada à hipoexpressão de miRNA-204. O tamanho do tumor foi associado à hiperexpressão de miRNA-21 e miRNA-301a e também à hipoexpressão de miRNA-29b e miRNA129-5p. Em relação à sobrevida global, menores taxas de sobrevida foram associadas à hiperexpressão de miRNA-21, miRNA-301a e microRNA-711 e à hipoexpressão de miRNA- 15a, miRNA-29b, miRNA-124, miRNA-129-5p, miRNA 199b-5p, miRNA-200b, miRNA-204, miRNA-206 e miRNA-218. Por outro lado, maiores taxas de sobrevida foram associadas à hiperexpressão de miRNA-339-5p e miRNA-127 e também à hipoexpressão de miRNA-210. Os resultados desta revisão enfatizam a necessidade de validar esses achados em estudos adicionais.
Downloads
Referências
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. https://doi.org/10.1002/ijc.29210
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2018-Incidência de câncer no Brasil. Brasil: Ministério da Saúde; 2017.
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al., eds. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8ª ed. Nova York: Springer; 2017.
Fang C, Wang F, Li Y, Zeng X. Down-regulation of miR-199b-5p is correlated with poor prognosis for breast câncer patients. Biomed Pharmacother. 2016;84:1189-93. https://doi.org/10.1016/j.biopha.2016.10.006
Hu J, Yi W, Zhang M, Xu R, Zeng L, Long X, et al. MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer. Oncol Lett. 2016;11(3):2155-63. https://dx.doi.org/10.3892%2Fol.2016.4217
Ahmadinejad F, Mowla SJ, Honardoost MA, Arjenaki MG, Moazeni-Bistgani M, Kheiri S, et al. Lower expression of miR-218 in human breast cancer is associated with lymph node metastases, higher grades, and poorer prognosis. Tumour Biol. 2017;39(8). https://doi.org/10.1177/1010428317698362
MacFarlane L-AR, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2010;11(7):537-61. https://dx.doi.org/10.2174%2F138920210793175895
Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev. 2009;35(4):328-34. https://doi.org/10.1016/j.ctrv.2008.12.002
Iorio MV, Croce CM. MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 2009;27(34):5848-56. https://doi.org/10.1200/JCO.2009.24.0317
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGFb. Breast Cancer Res Treat. 2009;117(1):131-40. https://doi.org/10.1007/s10549-008-0219-7
Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang X, et al. Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer. Med Oncol. 2014;31(11):283. https://doi.org/10.1007/s12032-014-0283-2
Shinden Y, Iguchi T, Akiyoshi S, Ueo H, Ueda M, Hirata H, et al. miR‑29b is an indicator of prognosis in breast cancer patients. Mol Clin Oncol. 2015;3(4):919-23. https://dx.doi.org/10.3892%2Fmco.2015.565
Dong L, Chen L, Wang W, Zhang L. Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer. Diagn Pathol. 2015;10:45. https://doi.org/10.1186/s13000-015-0257-5
Yan L, Huang X, Shao Q, Huang M, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast câncer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14(11):2348-60. https://doi.org/10.1261/rna.1034808
Sim J, Ahn H, Abdul R, Kim H, Yi K, Chung Y, et al. High MicroRNA-370 Expression Correlates with Tumor Progression and Poor Prognosis in Breast Cancer. J Breast Cancer. 2015;18(4):323-8. https://doi.org/10.4048/jbc.2015.18.4.323
Wang S, Li H, Wang J, Wang D, Yao A, Li Q. Prognostic and Biological Significance of MicroRNA-127 Expression in Human Breast Cancer. Dis Markers. 2014;2014:401986. https://doi.org/10.1155/2014/401986
Yu Y, Zhao Y, Sun X, Ge J, Zhang B, Wang X, et al. Downregulation of miR-129-5p via the Twist1-Snail feedback loop stimulates the epithelial-mesenchymal transition and is associated with poor prognosis in breast cancer. Oncotarget. 2015;6(33):34423-36. https://doi.org/10.18632/oncotarget.5406
Li Y, Hong F, Yu Z. Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival. J Int Med Res. 2013;41(3):596-602. https://doi.org/10.1177/0300060513485856
Wu Z, Wu Q, Wang C, Wang X, Wang Y, Zhao J, et al. MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer. 2010;10:542. https://doi.org/10.1186/1471-2407-10-542
Li W, Jin X, Zhang Q, Zhang G, Deng X, Ma L. Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol. 2014;7(6):3287-92.
Ye F, Tang H, Liu Q, Xie X, Wu M, Liu X, et al. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. J Transl Med. 2014;12:17. https://doi.org/10.1186/1479-5876-12-17
Lee JA, Lee HY, Lee ES, Kim I, Bae JW. Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. J Breast Cancer. 2011;14(4):269-75. https://doi.org/10.4048/jbc.2011.14.4.269
Dong G, Liang X, Wang D, Gao H, Wang L, Wang L, et al. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol. 2014;31(7):57. https://doi.org/10.1007/s12032-014-0057-x
Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, et al. High Expression of MicroRNA-210 is an Independent Factor Indicating a Poor Prognosis in Japanese Triple-negative Breast Cancer Patients. Jpn J Clin Oncol. 2012;42(4):256-63. https://doi.org/10.1093/jjco/hys001
Yao Y, Hu J, Shen Z, Yao R, Liu S, Li Y, et al. MiR-200b expression in breast cancer : a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1. J Cell Mol Med. 2015;19(4):760-9. https://doi.org/10.1111/jcmm.12432
Shinden Y, Akiyoshi S, Ueo H, Nambara S, Saito T, Komatsu H, et al. Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res. 2015;35(1):123-7.
Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2017;172:34-49. https://doi.org/10.1016/j.pharmthera.2016.11.012
van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015;17(1):1-15. https://dx.doi.org/10.1186%2Fs13058-015-0526-y
Bertoli G, Cava C, Castiglioni I. Micrornas: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5(10):1122-43. https://doi.org/10.7150/thno.11543
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2018 Bárbara Adaildes dos Santos Soares, Karlla Greick Batista Dias Penna, Vera Aparecida Saddi
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
